Olatz Arrizabalaga

Olatz Arrizabalaga

Auto-generated profile, based on publicly available information

Olatz Arrizabalaga

Innovation Unit, Biodonostia Health Research Institute, San Sebastián, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2016 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Open access
LGLaura Garros-Regulez
Laura Garros-Regulez
PAPaula Aldaz
Paula Aldaz
OAOlatz Arrizabalaga
Olatz Arrizabalaga
VMVeronica Moncho
Veronica Moncho
ECEstefania Carrasco-Garcia
Estefania Carrasco-Garcia
Ander MatheuAnder Matheu
Ander Matheu
Background: SOX2 and SOX9 are commonly overexpressed in glioblastoma, and regulate the activity of glioma stem cells (GSCs). Their specific and overlapping roles in GSCs and glioma treatment remain...

24 October 2016 in Frontiers in Oncology
Verified
Journal Article
Open access
LGLaura Garros-Regulez
Laura Garros-Regulez
IGIdoia Garcia
Idoia Garcia
ECEstefania Carrasco-Garcia
Estefania Carrasco-Garcia
ALAquilino Lantero
Aquilino Lantero
PAPaula Aldaz
Paula Aldaz
Ander MatheuAnder Matheu
Ander Matheu
Glioblastoma is the most common and malignant brain cancer in adults. Current therapy consisting of surgery followed by radiation and temozolomide therapy has moderate success rate and the tumor reappears. Among the features that a cancer cell must have to survive the therapeutic treatment and reconstitute the tumor is the ability to self-renewal. Therefore, it is vital to identify the molecular mechanisms that regulate this activity. SOX2 is a transcription factor whose activity has been associated with the maintenance of the undifferentiated state of cancer stem cells in several tissues including the brain. Several groups have detected SOX2 levels increased in biopsies of glioblastoma patients, with highest levels associated to poor outcome. Therefore, SOX2 silencing might be a novel therapeutic approach to combat cancer and particularly brain tumors.In this review, we will summarize the current knowledge about SOX2 in glioblastoma and recapitulate several strategies, which have been recently described targeting SOX2 in this malignancy.

20 May 2015 in Aging Cell
Verified
Journal Article
Open access
PDF file
ECEstefania Carrasco-Garcia
Estefania Carrasco-Garcia
OAOlatz Arrizabalaga
Olatz Arrizabalaga
MSManuel Serrano
Manuel Serrano
RLRobin Lovell-Badge
Robin Lovell-Badge
Ander MatheuAnder Matheu
Ander Matheu
The impairment of the activity of the brain is a major feature of aging, which coincides with a decrease in the function of neural stem cells. We have previously shown that an extra copy of regulated Ink4/Arf and p53 activity, in s‐Ink4/Arf/p53 mice, elongates lifespan and delays aging. In this work, we examined the physiology of the s‐Ink4/Arf/p53 brain with aging, focusing on the neural stem cell (NSC) population. We show that cells derived from old s‐Ink4/Arf/p53 mice display enhanced neurosphere formation and self‐renewal activity compared with wt controls. This correlates with augmented expression of Sox2, Sox9, Glast, Ascl1, and Ars2 NSC markers in the subventricular zone (SVZ) and in the subgranular zone of the dentate gyrus (DG) niches. Furthermore, aged s‐Ink4/Arf/p53 mice express higher levels of Doublecortin and PSA‐NCAM (neuroblasts) and NeuN (neurons) in the olfactory bulbs (OB) and DG, indicating increased neurogenesis in vivo. Finally, aged s‐Ink4/Arf/p53 mice present enhanced behavioral and neuromuscular coordination activity. Together, these findings demonstrate that increased but regulated Ink4/Arf and p53 activity ameliorates age‐related deterioration of the central nervous system activity required to maintain the stem cell pool, providing a mechanism not only for the extended lifespan but also for the health span of these mice.

14 December 2017 in Oncogenesis
Verified
Journal Article
Open access
PDF file
OAOlatz Arrizabalaga
Olatz Arrizabalaga
LMLeire Moreno-Cugnon
Leire Moreno-Cugnon
JAJaione Auzmendi-Iriarte
Jaione Auzmendi-Iriarte
PAPaula Aldaz
Paula Aldaz
ICInmaculada Ibanez de Caceres
Inmaculada Ibanez de Caceres
Ander MatheuAnder Matheu
Ander Matheu
The elucidation of mechanisms involved in resistance to therapies is essential to improve the survival of patients with malignant gliomas. A major feature possessed by glioma cells that may aid their ability to survive therapy and reconstitute tumors is the capacity for self-renewal. We show here that glioma stem cells (GSCs) express low levels of MKP1, a dual-specificity phosphatase, which acts as a negative inhibitor of JNK, ERK1/2, and p38 MAPK, while induction of high levels of MKP1 expression are associated with differentiation of GSC. Notably, we find that high levels of MKP1 correlate with a subset of glioblastoma patients with better prognosis and overall increased survival. Gain of expression studies demonstrated that elevated MKP1 impairs self-renewal and induces differentiation of GSCs while reducing tumorigenesis in vivo. Moreover, we identified that MKP1 is epigenetically regulated and that it mediates the anti-tumor activity of histone deacetylase inhibitors (HDACIs) alone or in combination with temozolomide. In summary, this study identifies MKP1 as a key modulator of the interplay between GSC self-renewal and differentiation and provides evidence that the activation of MKP1, through epigenetic regulation, might be a novel therapeutic strategy to overcome therapy resistance in glioblastoma.

12 August 2020 in F1000Research
Verified
Journal Article
Open access
PDF file
OAOlatz Arrizabalaga
Olatz Arrizabalaga
DODavid Otaegui
David Otaegui
IVItziar Vergara
Itziar Vergara
JAJulio Arrizabalaga
Julio Arrizabalaga
EMEva Méndez
Eva Méndez
Background: The COVID-19 outbreak has made funders, researchers and publishers agree to have research publications, as well as other research outputs, such as data, become openly available. In this extraordinary research context of the SARS CoV-2 pandemic, publishers are announcing that their coronavirus-related articles will be made immediately accessible in appropriate open repositories, like PubMed Central (PMC), agreeing upon funders’ and researchers’ instigation. Methods: This work uses Unpaywall, OpenRefine and PubMed to analyse the level of openness of the papers about COVID-19, published during the first quarter of 2020. It also analyses Open Access (OA) articles published about previous coronavirus (SARS CoV-1 and MERS CoV) as a means of comparison. Results: A total of 5,611 COVID-19-related articles were analysed from PubMed. This is a much higher amount for a period of 4 months compared to those found for SARS CoV-1 and MERS during the first year of their first outbreaks (337 and 125 articles, respectively). Regarding the levels of openness, 97.4% of the SARS CoV-2 papers are freely available; similar rates were found for the other coronaviruses. Deeper analysis showed that (i) 68.3% of articles belong to an undefined Bronze category; (ii) 72.1% of all OA papers don’t carry a specific license and in all cases where there is, half of them do not meet Open Access standards; (iii) there is a large proportion that present a copy in a repository, in most cases in PMC, where this trend is also observed. These patterns were found to be repeated in most frequent publishers: Elsevier, Springer and Wiley. Conclusions: Our results suggest that, although scientific production is much higher than during previous epidemics and is open, there is a caveat to this opening, characterized by the absence of fundamental elements and values ​​on which Open Science is based, such as licensing.

27 September 2019 in Aging Cell
Verified
Journal Article
Open access
LMLeire Moreno-Cugnon
Leire Moreno-Cugnon
MRMiren Revuelta
Miren Revuelta
OAOlatz Arrizabalaga
Olatz Arrizabalaga
SCSandra Colie
Sandra Colie
MMManuel Moreno‐Valladares
Manuel Moreno‐Valladares
Ander MatheuAnder Matheu
Ander Matheu
Neuronal activity regulates cognition and neural stem cell (NSC) function. The molecular pathways limiting neuronal activity during aging remain largely unknown. In this work, we show that p38MAPK activity increases in neurons with age. By using mice expressing p38α‐lox and CamkII‐Cre alleles (p38α∆‐N), we demonstrate that genetic deletion of p38α in neurons suffices to reduce age‐associated elevation of p38MAPK activity, neuronal loss and cognitive decline. Moreover, aged p38α∆‐N mice present elevated numbers of NSCs in the hippocampus and the subventricular zone. These results reveal novel roles for neuronal p38MAPK in age‐associated NSC exhaustion and cognitive decline.